✍ Scribed by Thierry Simonart; Johan R. Boelaert; Graciela Andrei; Joost J. van den Oord; Chantale Degraef; Philippe Hermans; Jean-Christophe Noel; Jean-Paul Van Vooren; Michel Heenen; Erik De Clercq; Robert Snoeck
No coin nor oath required. For personal study only.
Iron is suspected to be involved in the induction and/or progression of various human tumors. More particularly, we have previously shown that iron may be involved in the pathogenesis of Kaposi's sarcoma (KS). We have also shown that the iron chelator desferrioxamine (DFO) has a potent anti‐KS activity in vitro, suggesting that it may represent a potential therapeutic approach for the treatment of KS. The present study was designed to investigate the effect of DFO on the growth of human KS xenografts in immunodeficient mice. Unexpectedly, we found that mice treated with DFO (400 mg/kg, 3 times weekly) (n = 30) exhibited a marked enhancement of tumor growth compared with control mice (n = 33) (230 ± 134 mm^2^ versus 143 ± 70 mm p < 0.01). No enhancement of tumor growth was seen in mice treated with iron‐saturated DFO. At least 2 findings suggest that this paradoxic pro‐KS activity occurred independently of mice iron stores. First, treatment with DFO had only a marginal effect on ferritin and hematocrit levels. Second, induction of effective iron depletion by an iron‐poor diet (6.7 mg iron/kg diet) (n = 23) did not have a deleterious effect on the growth of the KS xenografts. The lesions obtained from the DFO‐treated animals exhibited a significantly decreased apoptotic index (p < 0.05), indicating that some antiapoptotic mechanism induced by DFO may be operating in vivo to favour tumor growth. In conclusion, our data show that DFO has a stimulatory effect on KS growth in imunodeficient mice, suggesting that this drug is not indicated in patients with KS. © 2002 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Kaposi's sarcoma is currently the most common tumor in Zimbabwe. The purpose of our study is to compare the effectiveness of supportive care vs. 3 intervention approaches, namely oral Etoposide, a 3-drug combination, and radiotherapy using quality of life (QOL) as the primary measure of success. In
## Abstract We aimed to identify risk factors for Kaposi's sarcoma (KS) among HIV‐positive patients and behaviors associated with human Herpesvirus 8 (HHV‐8) infection, as well as to assess KS incidence and mortality rates longitudinally. To fulfill the first objective, a European case‐control stud